Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.12.2 (
MEK
)
18,161
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Lemur tyrosine kinase 3
(
LMTK3
) is a key member of the serine-threonine tyrosine kinase family. It plays an important role in breast cancer tumorigenesis and progression. However, its biological role in bladder cancer remains elusive. In this study, we demonstrated that
LMTK3
was overexpressed in bladder cancer and was positively correlated with bladder cancer malignancy. High
LMTK3
expression predicted poor overall survival. Knockdown of
LMTK3
in bladder cancer cells triggered cell-cycle arrest at G2/M phase, suppressed cell growth, and induced cell apoptosis in bladder cancer cells. Furthermore, Transwell assays revealed that reduction of
LMTK3
decreased cell migration by regulating the epithelial-to-mesenchymal transition pathway. Conversely, LKTM3 overexpression was shown to promote proliferation and migration of bladder cancer cells. We assessed phosphorylation of
MEK
and ERK1/2 in bladder cancer cells depleted of
LMTK3
and demonstrated a reduced phosphorylation status compared with the control group. Using an MAPK signaling-specific inhibitor, U0126, we could rescue the promotion of proliferation and viability in
LMTK3
-overexpressing cells. In conclusion, we extend the status of
LMTK3
as an oncogene in bladder cancer and provide evidence for its function via the activation of the ERK/MAPK pathway. Thus, targeting
LMTK3
may hold potential as a diagnostic and prognostic biomarker and as a possible future treatment for bladder cancer.
...
PMID:LMTK3 promotes tumorigenesis in bladder cancer via the ERK/MAPK pathway. 3286 71
